Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RNA-TEC was a specialized biotechnology company based in Leuven, Belgium, that focused on the chemical synthesis of high-purity RNA and modified oligonucleotides. Founded by Dr. Brian Sproat, a pioneer in nucleic acid chemistry, the company provided custom synthesis services for a wide range of research and therapeutic applications, including siRNA and long RNA sequences. RNA-TEC was particularly recognized for its expertise in producing complex, chemically modified RNA molecules that are difficult to synthesize using standard methods. In 2008, the company was acquired by Integrated DNA Technologies (IDT) to enhance IDT's global RNA synthesis capabilities and establish a manufacturing presence in Europe. Today, the expertise and technologies developed by RNA-TEC are fully integrated into IDT's core product offerings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RNA-TEC.